Stockwatch: J&J Earnings Show Benefits Of Diversity In Coronavirus
Group’s First-Quarter Results Likely To Echo Throughout 2020
Executive Summary
Amarin and J&J opened the first-quarter 2020 earnings season. Amarin’s financial report was a mere whisper compared with J&J’s sonic boom of better-than-expected Q1 financials. Nonetheless, J&J’s reduced guidance and divisional effects will echo through the sector and the year.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.